CCNU for the treatment of dogs with histiocytic sarcoma

Katherine A Skorupski, Craig A. Clifford, Melissa C. Paoloni, Ana Lara-Garcia, Lisa Barber, Michael S Kent, Amy K. LeBlanc, Aarti Sabhlok, Elizabeth A. Mauldin, Frances S. Shofer, C. Guillermo Couto, Karin U. Sørenmo

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Background: Histiocytic sarcoma is an aggressive neoplasm of dendritic cells that carries a grave prognosis. The efficacy of chemotherapy against this disease is unknown. The purpose of this study was to determine the efficacy of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in dogs with incompletely resected or metastatic histiocytic sarcoma, to describe the clinical characteristics of these dogs, and to identify factors affecting prognosis. Hypothesis: Our hypothesis is that CCNU has activity against canine histiocytic sarcoma and can improve survival in dogs with advanced disease. Animals: Included in analysis are dogs diagnosed with histiocytic sarcoma who had gross measurable or residual microscopic disease and who received CCNU. Methods: A multi-institutional, retrospective, single-arm cohort study was conducted. Available biopsy samples were tested with an antibody against CD18 when possible to confirm the diagnosis of histiocytic sarcoma. Results: Fifty-nine dogs were treated at 8 institutions. Twenty-three tumor specimens were confirmed to be CD18 positive. Treatment with CCNU at 60 to 90 mg/m2 resulted in an overall response rate of 46% in the 56 dogs with gross measurable disease. All 3 dogs with minimal residual disease experienced tumor relapse but lived 433 days or more after starting CCNU. The median survival of all 59 dogs was 106 days. Thrombocytopenia (<100,000 platelets/μL) and hypoalbuminemia were found to be negatively associated with prognosis and were predictive of <1 month survival. Conclusions and Clinical Importance: Results suggest that CCNU is active against canine histiocytic sarcoma and may be useful in the treatment of dogs without negative prognostic factors.

Original languageEnglish (US)
Pages (from-to)121-126
Number of pages6
JournalJournal of Veterinary Internal Medicine
Volume21
Issue number1
DOIs
StatePublished - Jan 2007

Fingerprint

Histiocytic Sarcoma
sarcoma
Dogs
dogs
Therapeutics
prognosis
Canidae
Hypoalbuminemia
Neoplasms
Residual Neoplasm
neoplasms
Thrombocytopenia
thrombocytopenia
Dendritic Cells
relapse
dendritic cells
cohort studies
Cohort Studies
Blood Platelets
drug therapy

Keywords

  • CD18
  • Dendritic cell neoplasia
  • Lomustine
  • Malignant histiocytosis

ASJC Scopus subject areas

  • veterinary(all)

Cite this

CCNU for the treatment of dogs with histiocytic sarcoma. / Skorupski, Katherine A; Clifford, Craig A.; Paoloni, Melissa C.; Lara-Garcia, Ana; Barber, Lisa; Kent, Michael S; LeBlanc, Amy K.; Sabhlok, Aarti; Mauldin, Elizabeth A.; Shofer, Frances S.; Couto, C. Guillermo; Sørenmo, Karin U.

In: Journal of Veterinary Internal Medicine, Vol. 21, No. 1, 01.2007, p. 121-126.

Research output: Contribution to journalArticle

Skorupski, KA, Clifford, CA, Paoloni, MC, Lara-Garcia, A, Barber, L, Kent, MS, LeBlanc, AK, Sabhlok, A, Mauldin, EA, Shofer, FS, Couto, CG & Sørenmo, KU 2007, 'CCNU for the treatment of dogs with histiocytic sarcoma', Journal of Veterinary Internal Medicine, vol. 21, no. 1, pp. 121-126. https://doi.org/10.1892/0891-6640(2007)21[121:CFTTOD]2.0.CO;2
Skorupski, Katherine A ; Clifford, Craig A. ; Paoloni, Melissa C. ; Lara-Garcia, Ana ; Barber, Lisa ; Kent, Michael S ; LeBlanc, Amy K. ; Sabhlok, Aarti ; Mauldin, Elizabeth A. ; Shofer, Frances S. ; Couto, C. Guillermo ; Sørenmo, Karin U. / CCNU for the treatment of dogs with histiocytic sarcoma. In: Journal of Veterinary Internal Medicine. 2007 ; Vol. 21, No. 1. pp. 121-126.
@article{ded1312ebebc4d43b75befab803193d8,
title = "CCNU for the treatment of dogs with histiocytic sarcoma",
abstract = "Background: Histiocytic sarcoma is an aggressive neoplasm of dendritic cells that carries a grave prognosis. The efficacy of chemotherapy against this disease is unknown. The purpose of this study was to determine the efficacy of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in dogs with incompletely resected or metastatic histiocytic sarcoma, to describe the clinical characteristics of these dogs, and to identify factors affecting prognosis. Hypothesis: Our hypothesis is that CCNU has activity against canine histiocytic sarcoma and can improve survival in dogs with advanced disease. Animals: Included in analysis are dogs diagnosed with histiocytic sarcoma who had gross measurable or residual microscopic disease and who received CCNU. Methods: A multi-institutional, retrospective, single-arm cohort study was conducted. Available biopsy samples were tested with an antibody against CD18 when possible to confirm the diagnosis of histiocytic sarcoma. Results: Fifty-nine dogs were treated at 8 institutions. Twenty-three tumor specimens were confirmed to be CD18 positive. Treatment with CCNU at 60 to 90 mg/m2 resulted in an overall response rate of 46{\%} in the 56 dogs with gross measurable disease. All 3 dogs with minimal residual disease experienced tumor relapse but lived 433 days or more after starting CCNU. The median survival of all 59 dogs was 106 days. Thrombocytopenia (<100,000 platelets/μL) and hypoalbuminemia were found to be negatively associated with prognosis and were predictive of <1 month survival. Conclusions and Clinical Importance: Results suggest that CCNU is active against canine histiocytic sarcoma and may be useful in the treatment of dogs without negative prognostic factors.",
keywords = "CD18, Dendritic cell neoplasia, Lomustine, Malignant histiocytosis",
author = "Skorupski, {Katherine A} and Clifford, {Craig A.} and Paoloni, {Melissa C.} and Ana Lara-Garcia and Lisa Barber and Kent, {Michael S} and LeBlanc, {Amy K.} and Aarti Sabhlok and Mauldin, {Elizabeth A.} and Shofer, {Frances S.} and Couto, {C. Guillermo} and S{\o}renmo, {Karin U.}",
year = "2007",
month = "1",
doi = "10.1892/0891-6640(2007)21[121:CFTTOD]2.0.CO;2",
language = "English (US)",
volume = "21",
pages = "121--126",
journal = "Journal of Veterinary Internal Medicine",
issn = "0891-6640",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - CCNU for the treatment of dogs with histiocytic sarcoma

AU - Skorupski, Katherine A

AU - Clifford, Craig A.

AU - Paoloni, Melissa C.

AU - Lara-Garcia, Ana

AU - Barber, Lisa

AU - Kent, Michael S

AU - LeBlanc, Amy K.

AU - Sabhlok, Aarti

AU - Mauldin, Elizabeth A.

AU - Shofer, Frances S.

AU - Couto, C. Guillermo

AU - Sørenmo, Karin U.

PY - 2007/1

Y1 - 2007/1

N2 - Background: Histiocytic sarcoma is an aggressive neoplasm of dendritic cells that carries a grave prognosis. The efficacy of chemotherapy against this disease is unknown. The purpose of this study was to determine the efficacy of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in dogs with incompletely resected or metastatic histiocytic sarcoma, to describe the clinical characteristics of these dogs, and to identify factors affecting prognosis. Hypothesis: Our hypothesis is that CCNU has activity against canine histiocytic sarcoma and can improve survival in dogs with advanced disease. Animals: Included in analysis are dogs diagnosed with histiocytic sarcoma who had gross measurable or residual microscopic disease and who received CCNU. Methods: A multi-institutional, retrospective, single-arm cohort study was conducted. Available biopsy samples were tested with an antibody against CD18 when possible to confirm the diagnosis of histiocytic sarcoma. Results: Fifty-nine dogs were treated at 8 institutions. Twenty-three tumor specimens were confirmed to be CD18 positive. Treatment with CCNU at 60 to 90 mg/m2 resulted in an overall response rate of 46% in the 56 dogs with gross measurable disease. All 3 dogs with minimal residual disease experienced tumor relapse but lived 433 days or more after starting CCNU. The median survival of all 59 dogs was 106 days. Thrombocytopenia (<100,000 platelets/μL) and hypoalbuminemia were found to be negatively associated with prognosis and were predictive of <1 month survival. Conclusions and Clinical Importance: Results suggest that CCNU is active against canine histiocytic sarcoma and may be useful in the treatment of dogs without negative prognostic factors.

AB - Background: Histiocytic sarcoma is an aggressive neoplasm of dendritic cells that carries a grave prognosis. The efficacy of chemotherapy against this disease is unknown. The purpose of this study was to determine the efficacy of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in dogs with incompletely resected or metastatic histiocytic sarcoma, to describe the clinical characteristics of these dogs, and to identify factors affecting prognosis. Hypothesis: Our hypothesis is that CCNU has activity against canine histiocytic sarcoma and can improve survival in dogs with advanced disease. Animals: Included in analysis are dogs diagnosed with histiocytic sarcoma who had gross measurable or residual microscopic disease and who received CCNU. Methods: A multi-institutional, retrospective, single-arm cohort study was conducted. Available biopsy samples were tested with an antibody against CD18 when possible to confirm the diagnosis of histiocytic sarcoma. Results: Fifty-nine dogs were treated at 8 institutions. Twenty-three tumor specimens were confirmed to be CD18 positive. Treatment with CCNU at 60 to 90 mg/m2 resulted in an overall response rate of 46% in the 56 dogs with gross measurable disease. All 3 dogs with minimal residual disease experienced tumor relapse but lived 433 days or more after starting CCNU. The median survival of all 59 dogs was 106 days. Thrombocytopenia (<100,000 platelets/μL) and hypoalbuminemia were found to be negatively associated with prognosis and were predictive of <1 month survival. Conclusions and Clinical Importance: Results suggest that CCNU is active against canine histiocytic sarcoma and may be useful in the treatment of dogs without negative prognostic factors.

KW - CD18

KW - Dendritic cell neoplasia

KW - Lomustine

KW - Malignant histiocytosis

UR - http://www.scopus.com/inward/record.url?scp=33847034820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847034820&partnerID=8YFLogxK

U2 - 10.1892/0891-6640(2007)21[121:CFTTOD]2.0.CO;2

DO - 10.1892/0891-6640(2007)21[121:CFTTOD]2.0.CO;2

M3 - Article

C2 - 17338159

AN - SCOPUS:33847034820

VL - 21

SP - 121

EP - 126

JO - Journal of Veterinary Internal Medicine

JF - Journal of Veterinary Internal Medicine

SN - 0891-6640

IS - 1

ER -